CD45: New jobs for an old acquaintance

Nature Immunology

Volumn 2, Issue 5, 2001, Pages 389-396

  Penninger, Josef M ^a   Irie Sasaki, Junko ^a,b   Sasaki, Takehiko ^a,b   Oliveira dos Santos, Antonio J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CYTOKINE RECEPTOR; PROTEIN TYROSINE KINASE;

AUTOIMMUNITY; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, CD45; AUTOIMMUNITY; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 0035347144     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/87687     Document Type: Review

References (102)

1. Trowbridge, I. S. & Thomas, M. L. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu. Rev. Immunol. 12, 85-116 (1994).
2. Thomas, M. L. The leukocyte common antigen family. Annu. Rev. Immunol. 7, 339-369 (1989).
3. Tonks, N. K., Charbonneau, H., Diltz, C. D., Fischer, E. H. & Walsh, K. A. Demonstration that the leukocyte common antigen CD45 is a protein tyrosine phosphatase. Biochemistry 27, 8695-8701. (1988).
4. Kishihara, K. et al. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 74, 143-156 (1993).
5. + thymocytes, and B cell maturation. J. Exp. Med. 183, 1707-1718 (1996).
6. Kozieradzki, I. et al. T cell development in mice expressing splice variants of the protein tyrosine phosphatase CD45. J. Immunol. 158, 3130-3139 (1997).
7. Koretzky, G. A., Picus, J., Thomas, M. L. & Weiss, A. Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway. Nature 346, 66-68 (1990).
8. Berger, S. A., Mak, T. W. & Paige, C. J. Leukocyte common antigen (CD45) is required for immunoglobulin E-mediated degranulation of mast cells. J. Exp. Med 180, 471-476 (1994).
9. Cale, C. M. et al. Severe combined immunodeficiency with abnormalities in expression of the common leucocyte antigen, CD45. Arch. Dis. Child. 76, 163-164 (1997).
10. Kung, C. et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nature Med. 6, 343-345 (2000).
11. Tchilian, E. Z. et al. A Deletion in the Gene Encoding the CD45 Antigen in a Patient with SCID. J. Immunol. 166, 1308-1313 (2001).
12. Irie-Sasaki, J. et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409, 349-354 (2001).
13. lck. Cell 55, 301-308 (1988).
14. Koretzky, G. A., Picus, J., Schultz, T. & Weiss, A. Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc. Natl Acad. Sci. USA 88, 2037-2041 (1991).
15. Felberg, J. & Johnson, P. Characterization of recombinant CD45 cytoplasmic domain proteins. Evidence for intramolecular and intermolecular interactions. J. Biol. Chem. 273, 17839-17845 (1998).
16. Johnson, P. & Felberg, J. CD45: a key regulator of Lck and T cell activation. Mod. Asp. Immunolbiol. 1, 147-151 (2001).
17. Cooper, J. A. & MacAuley, A. Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation. Proc. Natl Acad. Sci USA 85, 4232-4236. (1988).
18. Eck, M. J., Atwell, S. K., Shoelson, S. E. & Harrison, S. C. Structure of the regulatory domains of the Src family tyrosine kinase Lck. Nature 368, 764-769 (1994).
19. Mustelin, T. & Altman, A. Dephosphorylation and activation of the T cell tyrosine kinase pp56lck by the leukocyte common antigen (CD45). Oncogene 5, 809-513 (1990).
20. Seavitt, J. R. et al. Expression of the p56(Lck) Y505F mutation in CD45-deficient mice rescues thymocyte development. Mol. Cell Biol. 19, 4200-4208. (1999).
21. Roach, T. et al. CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Curr. Biol. 7, 408-417 (1997).
22. D'Oro, U. & Ashwell, J. D. The CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes. J. Immunol. 162, 1879-1883 (1999).
23. Yanagi, S. et al. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J. Biol. Chem. 271, 30487-30492 (1996).
24. Thomas, M. L. & Brown, E. J. Positive and negative regulation of Src family membrane kinases by CD45. Immunol. Today 20, 406-411 (1999).
25. Bergman, M. et al. The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J. 11, 2919-2924 (1992).
26. Chow, L. M., Fournel, M., Davidson, D. & Veillette, A. Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk. Nature 365, 156-160 (1993).
27. Kawabuchi, M. et al. Transmembrane phosphoprotein Cbp regulates the activities of Src family tyrosine kinases. Nature 404, 999-1003 (2000).
28. Takeuchi, S., Takayama, Y., Ogawa, A., Tamura, K. & Okada, M. Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk. J. Biol. Chem. 275, 29183-29186 (2000).
29. Brdicka, T. et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J. Exp. Med. 191, 1591-1604 (2000).
30. Autero, M. et al. Tyrosine phosphorylation of CD45 phosphotyrosine phosphatase by p50csk kinase creates a binding site for p56lck tyrosine kinase and activates the phosphatase. Mol. Cell Biol. 14, 1308-1321 (1994).
31. Ng, D. H., Watts, J. D., Aebersold, R. & Johnson, P. Demonstration of a direct interaction between p56lck and the cytoplasmic domain of CD45 in vitro. J. Biol. Chem. 271, 1295-1300 (1996).
32. Yamada, H., Kishihara, K., Kong, Y.Y. & Nomoto, K. Enhanced generation of NK cells with intact cytotoxic function in CD45 exon 6-deficient mice. J. Immunol. 157, 1523-1528 (1996).
33. Leonard, W. J. & O'Shea, J. J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293-322 (1998).
34. Campbell, G. S., Yu, C. L., Jove, R. & Carter-Su, C. Constitutive activation of JAK1 in Src-transformed cells. J. Biol. Cnem. 272, 2591-2594 (1997).
35. Chaturvedi, P., Sharma, S. & Reddy, E. P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell Biol. 17, 3295-3304 (1997).
36. Alexander, W. S. et al. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597-608 (1999).
37. Marine, J. C. et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98, 609-416 (1999).
38. Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921 (1997).
39. Endo, T.A. et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924 (1997).
40. Yasukawa, H. et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320 (1999).
41. Klingmuller, U., Lorenz, U., Cantley, L. C., Neel, B. G. & Lodish, H. F. Specific recruitment of SH-PTPI to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80, 729-738 (1995).
42. Haque, S. J., Harbor, P., Tabrizi, M., Yi, T. & Williams, B. R. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4-and IL-13-dependent signal transduction. J. Biol. Chem. 273, 33893-33896 (1998).
43. Ratei, R. et al. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. Ann. Hematol. 77, 107-114 (1998).
44. Ozdemirli, M., Mankin, H. J., Aisenberg, A. C. & Harris, N. L. Hodgkin's disease presenting as a solitary bone tumor. A report of four cases and review of the literature. Cancer 77, 79-88 (1996).
45. Ishikawa, H., Mahmoud, M. S., Fujii, R., Abroun, S. & Kawano, M. M. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk. Lymphoma 39, 51-55 (2000).
46. Baker, M. et al. Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice. EMBO J. 19, 4644-4654 (2000).
47. Trowbridge, I. S., Ostergaard, H. L. & Johnson, P. CD45: a leukocyte-specific member of the protein tyrosine phosphatase family. Biochim. Biophys. Acta 1095, 46-56 (1991).
48. Turka, L. A., Kanner, S. B., Schieven, G. L., Thompson, C. B. & Ledbetter, J. A. CD45 modulates T cell receptor/CD3-induced activation of human thymocytes via regulation of tyrosine phosphorylation. Eur J. Immunol. 22, 551-557 (1992).
49. Lazarovits, A. I. et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 380, 717-720 (1996).
50. Zhang, Z. et al. Prolongation of xenograft survival using monoclonal antibody CD45RB and cyclophosphamide in rat-to-mouse kidney and heart transplant models. Transplantation 69, 1137-1146 (2000).
51. Auersvald, L. A. et al. Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation 63, 1355-1358 (1997).
52. Tan, J., Town, T. & Mullan, M. CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway. J. Biol. Chem. 275, 37224-37231 (2000).
53. Tan, J. et al. CD45 opposes β-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J. Neurosci. 20, 7587-7594 (2000).
54. Basadonna, G. P. et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc. Natl Acad. Sci. USA 95, 3821-3826 (1998).
55. Fecteau, S. et al. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nature Immunol. 2, 58-43 (2001).
56. Ralph, S. J., Thomas, M. L., Morton, C. C. & Trowbridge, I. S. Structural variants of human T200 glycoprotein (leukocyte-common antigen). EMBO J. 6, 1251-1257 (1987).
57. Wang, H. Y., Xu, X., Ding, J. H., Bermingham, J. R. Jr & Fu, X. D. SC3S plays a role in T cell development and alternative splicing of CD45. Mol. Cell 7, 331-342 (2001).
58. high expression induced by thymic selection events. J. Exp. Med. 176, 1657-1663 (1992).
59. Uittenbogaart, C. H. et al. Interleukin-4 induces expression of the CD45RA antigen on human thymocyte subpopulations. Int. Immunol. 2, 1179-1187 (1990).
60. Bell, E. B. & Sparshott, S. M. Interconversion of CD45R subsets of CD4 T cells in vivo. Nature 348, 163-166 (1990).
61. Desai, D. M., Sap, J., Schlessinger, J. & Weiss, A. Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell 73, 541-554 (1993).
62. Volarevic, S. et al. Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains. Science 260, 541-544 (1993).
63. Hovis, R. R. et al. Rescue of signaling by a chimeric protein containing the cytoplasmic domain of CD45. Science 260, 544-546 (1993).
64. Jacobsen, M. et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nature Genet. 26, 495-499 (2000).
65. Cohen, P. L. & Eisenberg, R. A. 1pr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9, 243-269 (1991).
66. + T cells in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Int. Immunol. 5, 479-489 (1993).
67. + T cells in autoimmune infiltrates in experimental allergic encephalomyelitis. Int. Immunol. 6, 347-354 (1994).
68. + T lymphocytes in children with infantile cholestasis. Immunol. Lett. 75, 179-184 (2001).
69. + peripheral blood T-lymphocytes is related to auto-immune processes and hematological manifestations in systemic lupus erythematosus. Schweiz Med. Wochenschr. 126, 1922-1925 (1996).
70. Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285, 221-227 (1999).
71. Monks, C. R. F., Freiberg, B. A., Kupfer, H., Sciaky, N. & Kupfer, A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 82-86 (1998).
72. Shaw, A. S. & Dustin, M. L. Making the T cell receptor go the distance: A topological view of T cell activation. Immunity 6, 361-369 (1997).
73. Rodgers, W. & Rose, J. K. Exclusion of CD45 inhibits activity of p56lck associated with glycolipid-enriched membrane domains. J. Cell Biol. 135, 1515-1523 (1996).
74. Janes, P. W., Ley, S. C. & Magee, A. I. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J. Cell Biol. 147, 447-461 (1999).
75. Johnson, K. G., Bromley, S. K., Dustin, M. L. & Thomas, M. L. A supramolecular basis for CD45 tyrosine phosphatase regulation in sustained T cell activation. Proc. Natl Acad. Sci. USA 97, 10138-10143 (2000).
76. Leupin, O., Zaru, R., Laroche, T., Muller, S. & Valitutti, S. Exclusion of CD45 from the T-cell receptor signaling area in antigen-stimulated T lymphocytes. Curr. Biol. 10, 277-280 (2000).
77. Sperling, A. I. et al. TCR signaling induces selective exclusion of CD43 from the T cell-antigen-presenting cell contact site. J. Immunol. 161, 6459-6462 (1998).
78. Parolini, I., Sargiacomo, M., Lisanti, M. P. & Peschle, C. Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes. Blood 87, 3783-3794 (1996).
79. Volarevic, S., Burns, C. M., Sussman, J. J. & Ashwell, J. D. Intimate association of Thy-1 and the T-cell antigen receptor with the CD45 tyrosine phosphatase. Proc. Natl Acad. Sci. USA 87, 7085-7089 (1990).
80. Veillette, A. & Davidson, D. Src-related protein tyrosine kinases and T-cell receptor signalling. Trends Genet. 8, 61-66 (1992).
81. Majeti, R., Bilwes, A. M., Noel, J. P., Hunter, T. & Weiss, A. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 279, 88-91 (1998).
82. Jiang, G., den Hertog, J. & Hunter, T. Receptor-like protein tyrosine phosphatase α homodimerizes on the cell surface. Mol. Cell Biol. 20. 5917-5929 (2000).
83. Bilwes, A. M., den Hertog, J., Hunter, T. & Noel, J. P. Structural basis for inhibition of receptor protein-tyrosine phosphatase-α by dimerization. Nature 382, 555-559 (1996).
84. Majeti, R. et al. An Inactivating Point Mutation in the Inhibitory Wedge of CD45 Causes Lymphoproliferation and Autoimmunity. Cell 103, 1059-1070 (2000).
85. Wang, Y., Guo, W., Liang, L. & Esselman, W. J. Phosphorylation of CD45 by casein kinase 2. Modulation of activity and mutational analysis. J. Biol. Chem. 274, 7454-7461 (1999).
86. Stover, D. R. & Walsh, K. A. Protein-tyrosine phosphatase activity of CD45 is activated by sequential phosphorylation by two kinases. Mol. Cell Biol. 14, 5523-5532 (1994).
87. Fialkow, L., Chan, C. K. & Downey, G. P. Inhibition of CD45 during neutrophil activation. J. Immunol. 158, 5409-5417 (1997).
88. + T cells: specific inhibition of cytokine production but not proliferation of human naive T cells. Clin. Exp. Immunol. 121, 283-288, (2000).
89. Stover, D. R., Charbonneau, H., Tonks, N. K. & Walsh, K. A. Protein-tyrosine-phosphatase CD45 is phosphorylated transiently on tyrosine upon activation of Jurkat T cells. Proc. Natl. Acad. Sci. USA 88, 7704-7707 (1991).
90. Altin, J. G. & Sloan, E. K. The role of CD45 and CD45-associated molecules in T cell activation. Immunol. Cell Biol. 75, 430-445 (1997).
91. Schraven, B. et al. LPAP, a novel 32-kD phosphoprotein that interacts with CD45 in human lymphocytes. J. Biol. Chem. 269, 29102-29111 (1994).
92. Bruyns, E., Hendricks-Taylor, L. R., Meuer, S., Koretzky, G. A. & Schraven, B. Identification of the sites of interaction between lymphocyte phosphatase-associated phosphoprotein (LPAP) and CD45. J. Biol. Chem. 270, 31372-31376 (1995).
93. Matsuda, A. et al. Disruption of lymphocyte function and signaling in CD45-associated protein-null mice. J. Exp. Med. 187, 1863-1870 (1998).
94. Bruyns, E., Kirchgessner, H., Meuer, S. & Schraven, B. Biochemical analysis of the CD45-p56(lck) complex in Jurkat T cells lacking expression of lymphocyte phosphatase-associated phosphoprotein. Int. Immunol. 10, 185-194 (1998).
95. Ding, I. et al. Biochemical and functional analysis of mice deficient in expression of the CD45-associated phosphoprotein LPAP. Eur J. Immunol. 29, 3956-3961 (1999).
96. Kung, C. et al. CD45-associated protein is not essential for the regulation of antigen receptor-mediated signal transduction. Eur J. Immunol. 29, 3951-3955 (1999).
97. Stamenkovic, I., Sgroi, D., Aruffo, A., Sy, M. S. & Anderson, T. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2-6 sialyltransferase, CD75, on B cells. Cell 66, 1133-1144 (1991).
98. Sgroi, D., Varki, A., Braesch-Andersen, S. & Stamenkovic, I. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J. Biol. Chem. 268, 7011-7018 (1993).
99. Symons, A., Cooper, D. N. & Barclay, A. N. Characterization of the interaction between galectin-1 and lymphocyte glycoproteins CD45 and Thy-1. Glycobiology 10, 559-563. (2000).
100. Perillo, N. L., Pace, K. E., Seilhamer, J. J. & Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736-739 (1995).
101. Demetriou, M., Granovsky, M., Quaggin, S. & Dennis, J. W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733-739 (2001).
102. Petricoin, E. F. I. et al. Antiproliferative action of interferon-a requires components of T-cell-receptor signalling. Nature 390, 629-632 (1997).